Replimune (REPL)
8.74
-0.73 (7.71%)
Upcoming Events
Latest Headlines
Form 4 Replimune Group, Inc. For: Jun 01 Filed by: Sarchi Christopher
June 3, 2026 8:30 PM - SEC Filing
Replimune (REPL) call put ratio 1 call to 1.2 put amid sharp rally
June 1, 2026 5:42 AM - StreetInsider
Replimune presents final data for RP2 cancer treatment at oncology meeting
June 1, 2026 2:53 AM - StreetInsider
JPMorgan Upgrades Replimune Group (REPL) to Neutral
June 1, 2026 1:06 AM - StreetInsider
Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
May 31, 2026 8:00 AM - Globe NewsWire
Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
May 30, 2026 8:00 AM - StreetInsider
JPMorgan Upgrades Replimune Group (REPL) to Neutral
May 29, 2026 1:15 PM - StreetInsider
Replimune (REPL) call put ratio 1.4 calls to 1 put as share price up 83%
May 29, 2026 10:49 AM - StreetInsider
Form 8-K Replimune Group, Inc. For: May 29
May 29, 2026 9:56 AM - SEC Filing
Replimune plans RP1 cancer drug resubmission after FDA talks
May 29, 2026 8:01 AM - StreetInsider
Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA
May 29, 2026 8:00 AM - Globe NewsWire
Replimune To Resubmit Melanoma Treatment For Fda Approval - WSJ
May 29, 2026 7:33 AM - StreetInsider
Form SCHEDULE 13G Replimune Group, Inc. Filed by: Ridgeback Capital Investments L.P.
May 21, 2026 5:24 PM - SEC Filing
Form 4 Replimune Group, Inc. For: May 18 Filed by: Xynos Konstantinos
May 20, 2026 4:18 PM - SEC Filing
Form 4 Replimune Group, Inc. For: May 18 Filed by: Schwendenman Andrew
May 20, 2026 4:18 PM - SEC Filing
Form 4 Replimune Group, Inc. For: May 18 Filed by: Sarchi Christopher
May 20, 2026 4:17 PM - SEC Filing
Form 4 Replimune Group, Inc. For: May 18 Filed by: Astley-Sparke Philip
May 20, 2026 4:16 PM - SEC Filing
Form 4 Replimune Group, Inc. For: May 18 Filed by: Patel Sushil
May 20, 2026 4:16 PM - SEC Filing
Form 4 Replimune Group, Inc. For: May 18 Filed by: Hill Emily Luisa
May 20, 2026 4:16 PM - SEC Filing
Form SCHEDULE 13G/A Replimune Group, Inc. Filed by: RTW INVESTMENTS, LP
May 15, 2026 8:30 AM - SEC Filing
Form SCHEDULE 13G Replimune Group, Inc. Filed by: SUVRETTA CAPITAL MANAGEMENT, LLC
May 12, 2026 6:32 PM - SEC Filing
FDA Commissioner Marty Makary is resigning - Politico reporter on X
May 12, 2026 12:49 PM - StreetInsider
Replimune shares surge on report Trump to dismiss FDA chief Makary
May 8, 2026 1:32 PM - StreetInsider
Form SCHEDULE 13G/A Replimune Group, Inc. Filed by: PRICE T ROWE ASSOCIATES INC /MD/
May 7, 2026 11:05 AM - SEC Filing
Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
April 27, 2026 8:00 AM - Globe NewsWire
Increasing unusual option volume: REPL ALLO CORN ALMU IDYA TPG CNK PLCE IVR VIST TVTX
April 14, 2026 10:44 AM - StreetInsider
Increasing unusual option volume: REPL ALLO CORN ALMU IDYA TPG CNK PLCE IVR VIST TVTX
April 13, 2026 10:15 AM - StreetInsider
Replimune sinks 57% on second FDA rejection of melanoma drug; stock downgraded
April 13, 2026 6:44 AM - StreetInsider
Wedbush Downgrades Replimune Group (REPL) to Neutral
April 13, 2026 6:09 AM - StreetInsider
Leerink Partners Downgrades Replimune Group (REPL) to Market Perform
April 13, 2026 6:08 AM - StreetInsider
H.C. Wainwright Downgrades Replimune Group (REPL) to Sell
April 13, 2026 6:08 AM - StreetInsider
Form 8-K Replimune Group, Inc. For: Apr 10
April 13, 2026 6:02 AM - SEC Filing
BMO Capital Downgrades Replimune Group (REPL) to Underperform
April 13, 2026 3:41 AM - StreetInsider
Jefferies Downgrades Replimune Group (REPL) to Hold
April 13, 2026 3:41 AM - StreetInsider
JPMorgan Downgrades Replimune Group (REPL) to Underweight
April 13, 2026 1:54 AM - StreetInsider
Replimune receives FDA rejection for melanoma treatment RP1
April 10, 2026 5:04 PM - StreetInsider
Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
April 10, 2026 5:02 PM - Globe NewsWire
Cantor Fitzgerald Downgrades Replimune Group (REPL) to Neutral
April 10, 2026 4:04 PM - StreetInsider
Piper Sandler Downgrades Replimune Group (REPL) to Neutral
April 10, 2026 3:38 PM - StreetInsider
Jefferies on Iovanace Biotherapeutics (IOVA): 'we think the pot'l risk of competition was accounted for in Street models'
April 10, 2026 1:20 PM - StreetInsider
Replimune (REPL) gets CRL from FDA
April 10, 2026 11:18 AM - StreetInsider
Replimune (REPL) Halted on Volatility, Down 8%
April 10, 2026 10:57 AM - StreetInsider
Form 4 Replimune Group, Inc. For: Apr 01 Filed by: BAKER JULIAN
April 7, 2026 9:15 PM - SEC Filing
Form 4 Replimune Group, Inc. For: Apr 01 Filed by: Sarchi Christopher
April 7, 2026 9:12 PM - SEC Filing
Form 4 Replimune Group, Inc. For: Apr 01 Filed by: Astley-Sparke Philip
April 7, 2026 9:11 PM - SEC Filing
Form 4 Replimune Group, Inc. For: Apr 01 Filed by: Oliger Christy J.
April 7, 2026 9:11 PM - SEC Filing
Form 4 Replimune Group, Inc. For: Apr 01 Filed by: Xynos Konstantinos
April 7, 2026 9:10 PM - SEC Filing
Form 4 Replimune Group, Inc. For: Apr 01 Filed by: Balachandran Madhavan
April 7, 2026 9:10 PM - SEC Filing
Form 4 Replimune Group, Inc. For: Apr 01 Filed by: Schwendenman Andrew
April 7, 2026 9:10 PM - SEC Filing
Form 4 Replimune Group, Inc. For: Apr 01 Filed by: Patel Sushil
April 7, 2026 9:09 PM - SEC Filing
Form 4 Replimune Group, Inc. For: Apr 01 Filed by: Dhingra Kapil
April 7, 2026 9:09 PM - SEC Filing
Form 4 Replimune Group, Inc. For: Apr 01 Filed by: Pucci Paolo
April 7, 2026 9:09 PM - SEC Filing
Form 4 Replimune Group, Inc. For: Apr 01 Filed by: SLATTERY JOSEPH P
April 7, 2026 9:08 PM - SEC Filing
Form 4 Replimune Group, Inc. For: Apr 01 Filed by: Peeples-Dyer Veleka
April 7, 2026 9:08 PM - SEC Filing
Form 4 Replimune Group, Inc. For: Apr 01 Filed by: Hill Emily Luisa
April 7, 2026 9:08 PM - SEC Filing
Form 4 Replimune Group, Inc. For: Apr 01 Filed by: Weinand Dieter
April 7, 2026 9:08 PM - SEC Filing
Form 4 Replimune Group, Inc. For: Apr 02 Filed by: Sarchi Christopher
April 6, 2026 4:31 PM - SEC Filing
Increasing unusual option volume: VFS CORN CODI BIZD CWAN REPL
April 5, 2026 10:29 AM - StreetInsider
Form 144 Replimune Group, Inc. Filed by: Sarchi Christopher
April 2, 2026 4:16 PM - SEC Filing
Full Article List